Ticker
ALBO

Price
22.11
Stock movement down
-0.20 (-0.90%)
Company name
Albireo Pharma Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
432.83M
Ent value
329.25M
Price/Sales
9.52
Price/Book
2.92
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-11.77%
3 year return
5.15%
5 year return
-2.82%
10 year return
-11.57%
Last updated: 2022-11-24

DIVIDENDS

ALBO does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales9.52
Price to Book2.92
EV to Sales7.25

FINANCIALS

Per share

Loading...
Per share data
Current share count19.58M
EPS (TTM)-1.70
FCF per share (TTM)-5.66

Income statement

Loading...
Income statement data
Revenue (TTM)45.45M
Gross profit (TTM)43.85M
Operating income (TTM)-123.27M
Net income (TTM)-32.73M
EPS (TTM)-1.70
EPS (1y forward)-3.67

Margins

Loading...
Margins data
Gross margin (TTM)96.50%
Operating margin (TTM)-271.24%
Profit margin (TTM)-72.02%

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash216.66M
Net receivables1.27M
Total current assets228.73M
Goodwill17.26M
Intangible assets0.00
Property, plant and equipment0.00
Total assets261.26M
Accounts payable6.37M
Short/Current long term debt10.08M
Total current liabilities31.51M
Total liabilities113.08M
Shareholder's equity148.19M
Net tangible assets130.93M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-108.25M
Capital expenditures (TTM)979.00K
Free cash flow (TTM)-109.23M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-22.09%
Return on Assets-12.53%
Return on Invested Capital-22.09%
Cash Return on Invested Capital-73.71%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open22.41
Daily high22.74
Daily low21.70
Daily Volume109K
All-time high2995.20
1y analyst estimate70.40
Beta0.93
EPS (TTM)-1.70
Dividend per share-
Ex-div date-
Next earnings date27 Feb 2023

Downside potential

Loading...
Downside potential data
ALBOS&P500
Current price drop from All-time high-99.26%-15.76%
Highest price drop-99.77%-56.47%
Date of highest drop17 Dec 20159 Mar 2009
Avg drop from high-89.92%-11.46%
Avg time to new high261 days13 days
Max time to new high3745 days1805 days
COMPANY DETAILS
ALBO (Albireo Pharma Inc) company logo
Marketcap
432.83M
Marketcap category
Small-cap
Description
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.
Employees
130
Investor relations
-
SEC filings
CEO
Ronald H. W. Cooper
Country
USA
City
Boston
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that...
November 10, 2022
BOSTON, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced...
November 9, 2022
Albireo Pharma (ALBO) delivered earnings and revenue surprises of -1.61% and 1.58%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
November 8, 2022
Bylvay® (odevixibat) Q3 2022 PFIC net revenue of $7.5 million, September YTD 2022 $18.1 millionNew disease modification and native liver survival data with Bylvay in PFIC patients presented at AASLD P...
November 8, 2022
Early, rapid, and sustained efficacy across wide range of patients with evidence of disease modificationLong-term preservation of native liver in PFIC, improvements in pruritus, bile acids, and increa...
November 7, 2022
— Eight projects selected for inaugural year of the program — Projects provide solutions to make a tangible difference in the lives of PFIC patients BOSTON, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Albireo P...
November 3, 2022
– BOLD is the first, largest, and only global Phase 3 trial designed to meet regulatory agencies' requirements – On track to report topline data by the end of 2024, reinforcing Bylvay's expected posit...
November 2, 2022
Celldex (CLDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
November 1, 2022
– Oral late breaker with new results from positive Phase 3 ASSERT study in Alagille syndrome (ALGS) – Oral late breaker provides evidence of disease modification in PFIC – Analysis of PEDFIC 1 data sh...
November 1, 2022
Conference call and webcast to be held at 4:30 pm ETBOSTON, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, t...
October 31, 2022
Next page